OTCMKTS:BTCY

Biotricity - BTCY Stock Forecast, Price & News

$0.81

+0.03 (+3.85%)

(As of 09/28/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.78
▼
$0.89
50-Day Range: $0.78
▼
$1.49
52-Week Range: $0.75
▼
$5.30

Volume: 104,704 shs
Average Volume: 121,577 shs
Market Capitalization: $42.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.67

Biotricity MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 599.6% Upside
$5.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.33) to ($0.16) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Biotricity has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.67, Biotricity has a forecasted upside of 599.6% from its current price of $0.81.
Amount of Analyst Coverage
Biotricity has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BTCY.

0.0

Dividend Strength

Dividend Yield
Biotricity does not currently pay a dividend.
Dividend Growth
Biotricity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BTCY.

0.0

News and Social Media Coverage

Search Interest
Only 4 people have searched for BTCY on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Biotricity to their MarketBeat watchlist in the last 30 days. This is a decrease of -99% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biotricity insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 5.11% of the stock of Biotricity is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biotricity are expected to grow in the coming year, from ($0.33) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biotricity is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biotricity is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Biotricity (OTCMKTS:BTCY) Stock

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Receive BTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter.

BTCY Stock News Headlines

September 15, 2022 | streetinsider.com

Diagnostic Electrocardiograph Market to hit US$ 14.83 Billion by 2030 | Exclusive Report by Growth Plus Reports - StreetInsider.com

September 7, 2022 | globenewswire.com

Smart Pregnancy Tracker Market is estimated to be US$ 13.2 Billion by 2020 with a CAGR of 17.4% during the forecast period 2030 - By PMI - GlobeNewswire

September 7, 2022 | finance.yahoo.com

Biotricity Wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney Failure - Yahoo Finance

September 7, 2022 | finance.yahoo.com

Biotricity Wins NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled Real-Time Monitoring and Predictive Analytics for Stroke due to Chronic Kidney Failure

September 5, 2022 | businesswire.com

Global External Remote Patient Monitoring Devices Pipeline Report 2022: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies - ResearchAndMarkets.com - Business Wire

September 2, 2022 | forbes.com

Waqaas Al-siddiq - Forbes

August 30, 2022 | msn.com

BTCY: Health Monitoring Ecosystem is Expanding With New & Upcoming Products - msnNOW

August 30, 2022 | finance.yahoo.com

BTCY: Health Monitoring Ecosystem is Expanding With New & Upcoming Products

August 11, 2022 | benzinga.com

Majority of US Consumers Intending to Purchase Wearables Are Willing to Pay More For Devices With Health - Benzinga

August 5, 2022 | finance.yahoo.com

Biotricity to Host Fiscal First Quarter 2023 Financial Results Conference Call on August 15th at 4:30 p.m. ET

July 28, 2022 | seekingalpha.com

Biotricity Stock: A First Take (NASDAQ:BTCY) - Seeking Alpha

July 27, 2022 | finance.yahoo.com

Pregnancy Care Products Market to Index Promising Growth of USD 43.05 Million by 2029: Size, Share, Industry Analysis, regional Growth, Trends and Value Forecast - Yahoo Finance

July 19, 2022 | streetinsider.com

Form 8-K BIOTRICITY INC. For: Jul 14 - StreetInsider.com

July 16, 2022 | finance.yahoo.com

Biotricity Reports Financial Results for Fiscal 2022 Fourth Quarter and Full Year - Yahoo Finance

July 15, 2022 | benzinga.com

Looking Into Biotricity's Return On Capital Employed - Benzinga - Benzinga

July 11, 2022 | finance.yahoo.com

The market for Cardiac Arrhythmia Monitoring Devices will achieve a market value of USD 35.41 billion by 2030. - Yahoo Finance

June 29, 2022 | globenewswire.com

Registering a CAGR of 6.8% from 2022 to 2030, The Cardiac - GlobeNewswire

June 23, 2022 | finance.yahoo.com

Biotricity to Join Russell Microcap(R) Index

June 16, 2022 | seekingalpha.com

Bone Biologics, Akero top healthcare gainers; AC Immune, Arcellx lead losers' pack - Seeking Alpha

May 29, 2022 | nasdaq.com

Biotricity Now the Least Expensive vs. Bitcoin This Year

May 23, 2022 | finance.yahoo.com

Biotricity to Present at the 2022 H.C. Wainwright Global Investment Conference on Tuesday May 24th

May 5, 2022 | finance.yahoo.com

Biotricity Issues Shareholder Update - Yahoo Finance

May 5, 2022 | finance.yahoo.com

Biotricity Issues Shareholder Update

May 3, 2022 | finance.yahoo.com

SPYR Technologies’ Applied Magix Considers Expanding Into LED Smart Home Lighting Products - Yahoo Finance

May 3, 2022 | finance.yahoo.com

Citius Pharmaceuticals, Inc. Provides Business Update, Highlights Upcoming Milestones - Yahoo Finance

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biotricity and its competitors with MarketBeat's FREE daily newsletter.

BTCY Company Calendar

Last Earnings: 7/14/2022
Today: 9/28/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BTCY
CUSIP: N/A
CIK: 1630113
Web: www.biotricity.com
Phone: (650) 832-1626
Fax: N/A
Employees: 44
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.67
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +599.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.63)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,130,000.00
Net Margins: -360.56%
Pretax Margin: -380.78%
Return on Equity: N/A
Return on Assets: -160.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.37
Quick Ratio: 2.06

Sales & Book Value

Annual Sales: $7.70 million
Price / Sales: 5.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.04) per share
Price / Book: -20.25

Miscellaneous

Outstanding Shares: 51,898,000
Free Float: N/A
Market Cap: $42.04 million
Optionable: Not Optionable
Beta: 1.69

Key Executives

Dr. Waqaas Al-Siddiq Ph.D. (Age 37)
Founder, Pres, CEO & Chairman
Comp: $717k

Mr. S. John Ayanoglou (Age 56)
Chief Financial Officer
Comp: $387k

Dr. George N. Nikopoulos
Director of Bus. Devel.

Mr. Amir Ali
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BTCY Stock - Frequently Asked Questions

Should I buy or sell Biotricity stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biotricity in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BTCY shares.
View BTCY analyst ratings or view top-rated stocks.
What is Biotricity's stock price forecast for 2022?: 3 brokers have issued 1 year price targets for Biotricity's stock. Their BTCY share price forecasts range from $4.00 to $7.00. On average, they predict the company's stock price to reach $5.67 in the next year. This suggests a possible upside of 626.5% from the stock's current price.
View analysts price targets for BTCY or view top-rated stocks among Wall Street analysts.
How have BTCY shares performed in 2022?: Biotricity's stock was trading at $3.98 at the start of the year. Since then, BTCY stock has decreased by 80.4% and is now trading at $0.78.
View the best growth stocks for 2022 here.
When is Biotricity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our BTCY earnings forecast.
How were Biotricity's earnings last quarter?: Biotricity, Inc. (OTCMKTS:BTCY) released its quarterly earnings results on Thursday, July, 14th. The company reported ($0.12) EPS for the quarter. The firm had revenue of $2.15 million for the quarter.

What other stocks do shareholders of Biotricity own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biotricity investors own include Axsome Therapeutics (AXSM), Bank of America (BAC), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Broadcom (AVGO), Cannabix Technologies (BLOZF), BioLineRx (BLRX), CV Sciences (CVSI) and Charlotte's Web (CWBHF).
What is Biotricity's stock symbol?: Biotricity trades on the OTCMKTS under the ticker symbol "BTCY."
Who are Biotricity's major shareholders?: Biotricity's stock is owned by a number of retail and institutional investors. Top institutional investors include Signature Wealth Management Partners LLC (0.07%), Bouchey Financial Group Ltd (0.05%), Bouchey Financial Group Ltd (0.05%), Cedar Mountain Advisors LLC (0.03%), Concourse Financial Group Securities Inc. (0.00%) and Group One Trading L.P. (0.00%).
View institutional ownership trends.
How do I buy shares of Biotricity?: Shares of BTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biotricity's stock price today?: One share of BTCY stock can currently be purchased for approximately $0.78.
How much money does Biotricity make?: Biotricity (OTCMKTS:BTCY) has a market capitalization of $40.48 million and generates $7.70 million in revenue each year. The company earns $-29,130,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.
How can I contact Biotricity?: The official website for the company is www.biotricity.com. The company can be reached via phone at (650) 832-1626 or via email at investors@biotricity.com.

This page (OTCMKTS:BTCY) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biotricity - BTCY Stock Forecast, Price & News

Biotricity MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Biotricity (OTCMKTS:BTCY) Stock

BTCY Stock News Headlines

BTCY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BTCY Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™